Skip to main content

Table 1 Epitope specification of tested monoclonal antibodies

From: Differential glycosylation of envelope gp120 is associated with differential recognition of HIV-1 by virus-specific antibodies and cell infection

Monoclonal antibody Epitope structure Epitope Direct involvement of glycans in epitope formation Different reactivity with individual gp120 glycoforms* Glycan-shielding effect** Dilution corresponding to linear range in ELISA (μg per ml)* References
268 D4 V3 loop tip HIGPGR linear - + + 0.03 [51, 70]
257 D4 V3 loop stem KRIHI linear - + + 0.01 [51, 70]
F425 B4e8 V3 loop tip involving GPGRA, Ile309, and Phe317 linear - - + 0.04 [52, 71]
447-52D V3 loop tip GPGR plus amino acids at N-terminal segment of the V3 conformational - - + 0.07 [72, 73]
19b V3-loop tip -I----G--FY-T linear - + + 0.01 [74]
2G12 Man α1,2 Man-containing oligo-mannose N- glycans on C2, C3, V4, and C4 conformational + + + 0.04 [75, 76]
PGT 121 V3 base together with multiple surrounding glycans conformational + + - 0.15 [77]
PG16 Epitope dependent on several glycosylation sites in the V1, V2, V3 loop mostly high-mannose conformational + + - 7 [45, 78]
PG9 Epitope dependent on several glycosylation sites in the V1, V2, V3 loop mostly high-mannose conformational + + - 6 [45, 78]
b12 CD4 binding site conformational - + - 0.01 [79, 80]
VRC03 CD4 binding site conformational - + - 7 [81, 82]
VRC01 CD4 binding site conformational - + + 0.15 [81, 82]
  1. *This study, conclusions based on the differences in mAb binding to individual gp120 glycoforms; ** this study, conclusion based on the partial N-glycan removal effect on mAb binding.